NEW YORK, June 24 (GenomeWeb News) - Iconix Pharmaceuticals will provide its chemogenomic profiling technology to Icos, the Mountain View, Calif.-based company said today.

 

Under the agreement, Icos will use Iconix's chemogenomics platform to study preclinical drug responses and to discover biomarkers to predict drug efficacy and side effects.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.